Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

Autor: Sun, Hongyan1, Sun, Xiaoteng2, Zhai, Xiaoyu1, Guo, Jingfeng3, Liu, Yutao1, Ying, Jianming4, Wang, Ziping1
Zdroj: Thoracic Cancer. Jan2016, Vol. 7 Issue 1, p61-65. 5p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje